亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

头孢吡肟 医学 内科学 优势比 单变量分析 人口 抗生素 多元分析 胃肠病学 生物 微生物学 环境卫生 抗生素耐药性 亚胺培南
作者
Nathaniel J. Rhodes,Joseph L. Kuti,David P. Nicolau,Scott Van Wart,Anthony M. Nicasio,Jiajun Liu,Benjamin J. Lee,Michael Neely,Marc H. Scheetz
出处
期刊:Antimicrobial Agents and Chemotherapy [American Society for Microbiology]
卷期号:60 (3): 1401-1410 被引量:53
标识
DOI:10.1128/aac.01956-15
摘要

The percentage of time that free drug concentrations remain above the MIC (fT>MIC) that is necessary to prevent mortality among cefepime-treated patients with Gram-negative bloodstream infections (GNBSI) is poorly defined. We conducted a retrospective study of adult patients with GNBSI. Eligible cases were frequency matched to ensure categorical representation from all MICs. Organism, MIC, infection source, gender, age, serum creatinine, weight, antibiotic history, and modified APACHE II score were collected from hospital records. Two population pharmacokinetic models (models 1 and 2) were used to impute exposures over the first 24 h in each patient from mean model parameters, covariates, and dosing history. From the imputed exposures, survival thresholds for fT>MIC were identified using classification and regression tree (CART) analysis and analyzed as nominal variables for univariate and multivariate regressions. A total of 180 patients were included in the analysis, of whom 13.9% died and 86.1% survived. Many patients (46.7% [n = 84/180]) received combination therapy with cefepime. Survivors had higher mean (standard deviation [SD]) fT>MIC than those who died (model 1, 74.2% [29.6%] versus 52.1% [33.8%], P < 0.001; model 2, 85.9% [24.0%] versus 64.4% [31.4%], P < 0.001). CART identified fT>MIC threshold values for greater survival according to models 1 and 2 at >68% and >74%, respectively. Survival was improved for those with fT>MIC of >68% (model 1 adjusted odds ratio [aOR], 7.12; 95% confidence interval [CI], 1.90 to 26.7; P = 0.004) and >74% (model 2 aOR, 6.48; 95% CI, 1.90 to 22.1) after controlling for clinical covariates. Similarly, each 1% increase in cefepime fT>MIC resulted in a 2% improvement in multivariate survival probability (P = 0.015). Achieving a cefepime fT>MIC of 68 to 74% was associated with a higher odds of survival for patients with GNBSI. Regimens targeting this exposure should be aggressively pursued.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
多情向日葵完成签到,获得积分20
2秒前
阿司匹林完成签到,获得积分20
3秒前
小孟吖完成签到 ,获得积分10
3秒前
英姑应助喜悦的如娆采纳,获得10
5秒前
8秒前
lc发布了新的文献求助10
14秒前
16秒前
和气生财君完成签到 ,获得积分10
20秒前
utopia发布了新的文献求助30
22秒前
赵君仪完成签到,获得积分10
31秒前
财路通八方完成签到 ,获得积分10
31秒前
怡然立轩完成签到 ,获得积分10
32秒前
Lucas应助阳光的涵菡采纳,获得10
42秒前
科研通AI6应助1212采纳,获得10
49秒前
科目三应助HaonanZhang采纳,获得10
53秒前
MchemG应助TXZ06采纳,获得30
56秒前
田様应助utopia采纳,获得30
1分钟前
绾妤完成签到 ,获得积分0
1分钟前
Hello应助DWH采纳,获得10
1分钟前
1分钟前
九月亦星完成签到 ,获得积分10
1分钟前
HaonanZhang发布了新的文献求助10
1分钟前
TXZ06完成签到,获得积分10
1分钟前
顾矜应助科研通管家采纳,获得30
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
科研通AI6应助科研通管家采纳,获得10
1分钟前
小马甲应助科研通管家采纳,获得10
1分钟前
科研通AI6应助djbj2022采纳,获得80
1分钟前
1分钟前
1分钟前
DWH发布了新的文献求助10
1分钟前
1分钟前
Owen应助HaonanZhang采纳,获得10
1分钟前
Orange应助圆圆的大脑采纳,获得10
1分钟前
DWH完成签到,获得积分10
1分钟前
Hanif5329完成签到,获得积分10
1分钟前
wenhaw完成签到 ,获得积分10
1分钟前
义气的代曼完成签到,获得积分10
2分钟前
伊绵好完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Treatise on Geochemistry (Third edition) 1600
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 1000
List of 1,091 Public Pension Profiles by Region 981
医养结合概论 500
On the application of advanced modeling tools to the SLB analysis in NuScale. Part I: TRACE/PARCS, TRACE/PANTHER and ATHLET/DYN3D 500
L-Arginine Encapsulated Mesoporous MCM-41 Nanoparticles: A Study on In Vitro Release as Well as Kinetics 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5458934
求助须知:如何正确求助?哪些是违规求助? 4564862
关于积分的说明 14297161
捐赠科研通 4489918
什么是DOI,文献DOI怎么找? 2459415
邀请新用户注册赠送积分活动 1449081
关于科研通互助平台的介绍 1424578